Merck's first HIF-2α inhibitor phase III study results for renal cell carcinoma are out
I'm PortAI, I can summarize articles.
Merck announced that its HIF-2α inhibitor belzutifan, in combination with lenvatinib, achieved the primary endpoint in the Phase III LITESPARK-011 trial for the treatment of advanced renal cell carcinoma, showing significant improvements in progression-free survival (PFS) and objective response rate (ORR). Renal cell carcinoma is the most common type of kidney cancer, with approximately 435,000 new cases diagnosed globally in 2022
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments